May 17, 2020

DuoFertility: An innovative new infertility solution

IVF
fertility
ovulation
infertility
Admin
2 min
DuoFertility Monitor
In vitro fertilisation, or IVF as it is more often known, is one of the major treatments against infertility. Describing a process in which a fertilise...

In vitro fertilisation, or IVF as it is more often known, is one of the major treatments against infertility. Describing a process in which a fertilised egg is placed into a woman’s womb, IVF is usually expensive and the chances of success are slim. IVF is quite an invasive treatment and although it can lead to pregnancy, a natural conception is what most couples crave.

DuoFertility is a revolutionary new fertility monitor that is designed to avoid the use of invasive procedures like IVF. Dr. Oriane Chausiaux, the Chief Scientific Officer and co-founder of Cambridge Temperature Concepts (CTC), says DuoFertility offers an “unrivalled level of convenience, accuracy and support” to couples who experience difficulty in conceiving.

CTC, formed by a group of scientists from Cambridge University, is responsible for the development of DuoFertility. It works by monitoring a woman’s basal temperature to identify her most fertile days and therefore offers couples the best chance of conceiving. The tiny sensor is worn in a stick-on patch under the arm and detects temperature changes in women that are related to ovulation. 

“DuoFertility combines unsurpassed accuracy with unbeatable convenience,” says Chausiaux. Unlike other ovulation detection products, “DuoFertility simply monitors a woman’s body temperature continuously whatever she does and wherever she goes.” The collected data is then transmitted wirelessly from the sensor to the DuoFertility reader and then downloaded to the DuoFertility Fertility centre in Cambridge, UK for analysis.

“DuoFertility takes 20,000 times more data than conventional fertility monitors,” according to Chausiaux and it identifies a woman’s most fertile days with an accuracy of up to 99 percent. “In a study of 99 patients who qualified for IVF treatment, six months of using DuoFertility was shown to be as effective as one cycle of IVF,” explains Chausiaux.

DuoFertility is also much more affordable that IVF. Priced at £495, it is one tenth of the cost of a typical cycle of IVF. The DuoFertility team are so confident the device will help couples to fall pregnant they are offering a refund if pregnancy is not achieved after using the product for a year.

Chausiaux concludes by saying: “So far, over 100 couples with significant fertility difficulties have conceived using DuoFertility, many of whom had already been through IVF and other invasive procedures without success. For the many couples who experience unexplained infertility, DuoFertility offers a much needed helping hand to achieve a natural pregnancy.”

Share article

Jun 18, 2021

Skin Analytics wins NHSX award for AI skin cancer tool 

AI
NHS
skincancer
Cancer
2 min
Skin Analytics uses AI to detect skin cancer and will be deployed across the NHS to ease patient backlogs

An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system. 

NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion. 

Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making. 

In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog. 

Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening. 

DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.

Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.

Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges. 

"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”

Share article